What motivates Parkinson’s disease patients to enter clinical trials?

Valadas, Anabela; Coelho, Miguel; Mestre, Tiago; Guedes, Leonor Correia; Finisterra, Maria; Noronha, Ana; Rosa, Mário Miguel; Sampaio, Cristina; Ferreira, Joaquim J.

doi:10.1016/j.parkreldis.2011.05.023

Cited by 26 publications

(37 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although arterial hypertension was the most frequent health condition, no cardiovascular problems were reported during the intervention period. The average perceived exertion was 12.8±1.1 (11)(12)(13)(14), which corresponds to 'somewhat hard' on the Borg Scale.…”

Section: Safetymentioning

confidence: 99%

“…It has been pointed out that the main obstacle to the implementation of clinical experiments in PD is patient recruitment 12,24 . The present study showed a low recruitment rate of 11% during the period of eight months.…”

Section: Recruitmentmentioning

confidence: 99%

“…The fact that the recruitment was performed before the doctor's appointment may have been a limitation of the study, since there was no referral from the neurologist. Some studies suggested that the recommendation of a neurologist plays a major role in a PD subject's decision to participate in an exercise program 12,26 . Valadas et al 12 showed that the neurologist's recommendation of a clinical trial had a more determining role in that decision Table 3.…”

Section: Recruitmentmentioning

confidence: 99%

“…Power training has been shown to be safe and well tolerated in older adults 10 , however there is a need to determine possible adverse events associated with the training of fast movements in frail, sedentary older adults with functional deficits 10,11 . There is still no evidence that this kind of exercise can be safe and tolerated by subjects with PD, although safety is the main concern for these subjects when deciding to participate in a clinical trial 12 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Recruitment rate, feasibility and safety of power training in individuals with Parkinson's disease: a proof-of-concept study

Lima

Rodrigues-de-Paula

2013

Braz. J. Phys. Ther.

View full text Add to dashboard Cite

| Background: It has been suggested that power training should be implemented in interventions in Parkinson's disease (PD). However, it is necessary to determine the feasibility and safety of training rapid movements in such individuals. Objectives: To determine the rate of recruitment of potential participants, the rate of attendance at training sessions, the levels of adherence to the intervention, and the rate of adverse events. Method: Patients with PD, users of the national public health system underwent power training of the lower limb muscles three times a week for 10 weeks. The number of people who were screened and recruited was recorded, as well as the rate of attendance at the training sessions and adherence to the intervention protocol. Safety was assessed by the presence of adverse events, pain, number of falls, and risk of injury associated with the intervention. Results: Over the course of eight months, 62 individuals were screened and only 13 completed the program. The rates of attendance and adherence were 88% and 97%, respectively. There were no adverse events during training. Two participants reported joint pain and one reported falls during the training period. Conclusions: The recruitment rate was low due to the subjects' difficulties with transportation and lack of interest. The high rates of adherence and attendance and the absence of adverse events suggest that power training is feasible and safe in PD.

show abstract

Section: Safetymentioning

confidence: 99%

Section: Recruitmentmentioning

confidence: 99%

Section: Recruitmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Recruitment rate, feasibility and safety of power training in individuals with Parkinson's disease: a proof-of-concept study

Lima

Rodrigues-de-Paula

2013

Braz. J. Phys. Ther.

View full text Add to dashboard Cite

show abstract

“…Other reasons cited (64% stating to help advance science and 52% to benefit others) were altruistic [5]. Risk of adverse events (50%) and worry over the nega tive effects of treatment (35%) were com monly cited reasons for nonparticipation in [5]. Age too can be a barrier.…”

Section: Why Patients Do Not Participatementioning

confidence: 99%

Trials and Tribulations of Clinical Research: Promoting Parkinson's Patient Participation

Stamford

Willocks

2013

Neurodegen. Dis. Manage.

View full text Add to dashboard Cite

Overcoming obstacles in Parkinson's disease

et al. 2012

View full text Add to dashboard Cite

Improved symptomatic and disease-modifying treatments are needed for Parkinson's disease (PD). Although significant advances have been made in the understanding of PD etiology, the translation of these discoveries into novel transformative therapies has been limited as a result of systemic challenges in PD drug development. Preclinical testing lacks clear standards and prioritization criteria for advancing therapies to the clinic. Clinical testing is marked by expensive, long, and uninformative studies. In parallel to these scientific challenges, funding of late-stage drug development has become increasingly scarce and risk averse. In this context, novel models of collaboration and funding are opening up new avenues for pursuing treatments. This review will discuss the most critical challenges in PD drug development and the innovative approaches being developed to overcome these hurdles.

show abstract

What motivates Parkinson’s disease patients to enter clinical trials?

Cited by 26 publications

References 19 publications

Recruitment rate, feasibility and safety of power training in individuals with Parkinson's disease: a proof-of-concept study

Recruitment rate, feasibility and safety of power training in individuals with Parkinson's disease: a proof-of-concept study

Trials and Tribulations of Clinical Research: Promoting Parkinson's Patient Participation

Overcoming obstacles in Parkinson's disease

Contact Info

Product

Resources

About